Manufacturer: ZPHC (Zhengzhou Pharmaceutical Co. Ltd)
Active Ingredient: Retatrutide
Form: 5 lyophilized vials × 4 mg each (total 20 mg)
Category: Metabolic & weight‑management research compound
Storage & Handling
-
Store refrigerated at 2–8 °C (35–46 °F)
-
Protect from light; keep vials sealed until reconstitution
-
Maintain cold‑chain integrity during shipping
-
For research use only — not approved for human consumption outside supervised protocols
| Parameter | Standard Range | Notes |
|---|---|---|
| Total content | 20 mg | 5 vials × 4 mg |
| Administration | Subcutaneous injection | Abdomen, thigh, or upper arm |
| Frequency | Weekly | Long half‑life supports once‑weekly dosing |
| Weekly dose | 2–5 mg | Escalated gradually in study protocols |
| Timing | Morning (fasted) | Enhances appetite suppression and metabolic response |
| Cycle length | 5–10 weeks | Commonly studied duration |
| Research focus | Appetite suppression, insulin sensitivity, weight‑loss | Triple incretin agonist |
